Frondoside a inhibits an MYC-driven medulloblastoma model derived from human-induced pluripotent stem cells

Yingchao Xue, Yi Fu, Fenghong Zhao, Gege Gui, Yuguo Li, Samuel Rivero-Hinojosa, Guanshu Liu, Yunqing Li, Shuli Xia, Charles G. Eberhart, Mingyao Ying

Research output: Contribution to journalArticlepeer-review

Abstract

Medulloblastoma (MB) is the most common malignant pediatric brain tumor. MYC-driven MBs, commonly found in the group 3 MB, are aggressive and metastatic with the worst prognosis. Modeling MYC-driven MB is the foundation of therapeutic development. Here, we applied a synthetic mRNA-driven strategy to generate neuronal precursors from human-induced pluripotent stem cells (iPSCs). These neuronal precursors were transformed by the MYC oncogene combined with p53 loss of function to establish an MYC-driven MB model recapitulating the histologic and transcriptomic hallmarks of group 3 MB. We further show that the marine compound Frondoside A (FA) effectively inhibits this MYC-driven MB model without affecting isogenic neuronal precursors with undetectable MYC expression. Consistent results from a panel of MB models support that MYC levels are positively correlated with FA's antitumor potency. Next, we show that FA suppresses MYC expression and its downstream gene targets in MB cells, suggesting a potential mechanism underlying FA's inhibitory effects on MYC-driven cancers. In orthotopic xenografts of MYC-driven MB, intratumoral FA administration potently induces cytotoxicity in tumor xenografts, significantly extends the survival of tumor-bearing animals, and enhances the recruitment of microglia/macrophages and cytotoxic T lymphocytes to tumors. Moreover, we show that MYC levels also predict FA potency in glioblastoma and non-small cell lung cancer cells. Taken together, this study provides an efficient human iPSC-based strategy for personalizable cancer modeling, widely applicable to mechanistic studies (e.g., genetic predisposition to cancer) and drug discovery. Our preclinical results justify the clinical translation of FA in treating MYC-driven MB and other human cancers.

Original languageEnglish (US)
Pages (from-to)1199-1209
Number of pages11
JournalMolecular cancer therapeutics
Volume20
Issue number6
DOIs
StatePublished - Jun 2021

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Frondoside a inhibits an MYC-driven medulloblastoma model derived from human-induced pluripotent stem cells'. Together they form a unique fingerprint.

Cite this